Clinical research of short-term and low dose valaciclovir for cytomegalovirus pneumonia prophylaxis in renal transplant recipients

SHEN Bing,LIU Zhihong,JIAO Yang,YUAN Xuelu,ZHANG Yuan,BAO Erdun,FAN Yu

DOI: https://doi.org/10.19577/j.cnki.issn10074406.2008.03.007

2008-01-01

Abstract:AIM To evaluate the efficacy and safety of short-term and low dose valaciclovir in prevention of cytomegalovirus(CMV) pneumonia after renal transplantation.METHODS The clinical data of 157 patients receiving first cadaveric renal transplantation between Dec.2002 and Dec.2005 were prospectively analyzed.These patients belonged to the group of donor cytomegalovirus(CMV) positive,recipient positive or negative(D+R+,D+R-).All the patients were randomized to 3 groups: group A with oral short-term and low dose valaciclovir(0.6 g,po,bid ×2 mo,followed with 0.3 g,po,bid×1 mo),group B with oral long-term and conventional dose valaciclovir(0.6 g,po,bid ×6 mo),and group C without prophylactic of CMV pneumonia.The incidence of CMV pneumonia within one year of post-transplantation was prospectively analyzed.RESULTS The incidence of CMV pneumonia in the patients was 13.46% in group A,14.81% in group B and 35.30% in group C respectively.The incidence of CMV pneumonia in group A or group B was lower than that in group C statistically(A and C:P=0.010,B and C:P=0.015).There was no difference between group A and group B statistically(P=0.842).CONCLUSION Oral short-term and low dose valaciclovir prophylaxis is an effective measurement to decrease the incidence of CMV pneumonia after renal transplantation;and the therapeutic effect and safety are as distinguished as those of long-term and conventional dose valaciclovir program.